[1]
R. Ovilla-Martinez, “Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting”, J Infect Dev Ctries, vol. 16, no. 01, pp. 63–72, Jan. 2022.